Ileosigmoid fistulas in Crohn disease are surgically managed in varying ways, which suggests a need for standardized guidelines.

No significant difference in the risk for MACE was observed between patients with IBD receiving JAK vs TNF inhibitors.

Mental health comorbidities are more prevalent among transgender and gender nonconforming adults with IBD than the general and IBD US populations.

Risankizumab for Crohn disease taken over a long-term extension results in clinically meaningful sustained HRQOL improvements.